Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Net Income: 2015-2025

Historic Net Income for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$104.8 million.

  • Intellia Therapeutics' Net Income rose 21.02% to -$104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.4 million, marking a year-over-year increase of 8.75%. This contributed to the annual value of -$486.5 million for FY2024, which is 4.51% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Net Income of -$104.8 million as of Q3 2025, which was down 2.11% from -$102.6 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Net Income registered a high of -$46.2 million during Q1 2021, and its lowest value of -$143.7 million during Q1 2022.
  • Its 3-year average for Net Income is -$115.6 million, with a median of -$118.4 million in 2023.
  • As far as peak fluctuations go, Intellia Therapeutics' Net Income plummeted by 211.02% in 2022, and later skyrocketed by 30.43% in 2023.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Net Income stood at -$79.9 million in 2021, then crashed by 31.06% to -$104.7 million in 2022, then fell by 21.67% to -$127.4 million in 2023, then increased by 1.27% to -$125.8 million in 2024, then increased by 21.02% to -$104.8 million in 2025.
  • Its Net Income stands at -$104.8 million for Q3 2025, versus -$102.6 million for Q2 2025 and -$112.2 million for Q1 2025.